Chimeric antigen receptor (CAR) T cell therapies have evolved from a research tool to a concept-shifting therapy with impressive responses in B cell malignancies. This Review summarizes the current state of the CAR T cell field, focusing on CD19- and B cell maturation antigen-directed CAR T cells—the most developed of the CAR T cell therapies. We discuss the many challenges to CAR T cell therapeutic success and innovations in CAR design and T cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies.

中文翻译：

---

工程增强型 CAR T 细胞可改善癌症治疗

嵌合抗原受体 (CAR) T 细胞疗法已从一种研究工具发展成为一种概念转变疗法，在 B 细胞恶性肿瘤中具有令人印象深刻的反应。本综述总结了 CAR T 细胞领域的现状，重点关注 CD19 和 B 细胞成熟抗原导向的 CAR T 细胞——最成熟的 CAR T 细胞疗法。我们讨论了 CAR T 细胞治疗成功面临的诸多挑战以及 CAR 设计和 T 细胞工程的创新，旨在将该治疗平台扩展到血液恶性肿瘤之外。